Form 8-K - Current report:
SEC Accession No. 0001641172-25-021039
Filing Date
2025-07-25
Accepted
2025-07-25 17:00:32
Documents
14
Period of Report
2025-07-24
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 7.01: Regulation FD Disclosure
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K form8-k.htm   iXBRL 8-K 42283
2 EX-99.1 ex99-1.htm EX-99.1 15349
  Complete submission text file 0001641172-25-021039.txt   257363

Data Files

Seq Description Document Type Size
3 XBRL SCHEMA FILE cldi-20250724.xsd EX-101.SCH 3075
4 XBRL DEFINITION FILE cldi-20250724_def.xml EX-101.DEF 26199
5 XBRL LABEL FILE cldi-20250724_lab.xml EX-101.LAB 34239
6 XBRL PRESENTATION FILE cldi-20250724_pre.xml EX-101.PRE 22360
16 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 3812
Mailing Address 4475 EXECUTIVE DRIVE SUITE 200 SAN DIEGO CA 92121
Business Address 4475 EXECUTIVE DRIVE SUITE 200 SAN DIEGO CA 92121 858-794-9600
Calidi Biotherapeutics, Inc. (Filer) CIK: 0001855485 (see all company filings)

EIN.: 862967193 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40789 | Film No.: 251152276
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)